JUNB and non-small cell lung carcinoma: Among the CK-positive NSCLC patients, 50% (8 out of 16) had the (CK+/JUNB+/CXCR4+) phenotype, 44% (7 out of 16) had the (CK+/JUNB+/CXCR4–) phenotype, 6% (1 out of 16) had the (CK+/JUNB–/CXCR4+) phenotype and 38% (6 out of 16) had the (CK+/JUNB–/CXCR4–) phenotype (Figure 2a).